Skip to main content

Table 1 Basic patient characteristics and blood stream infections (BSI).

From: Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients

Item Group 1
(heparin)
Group 2
(TauroLock™)
P value
No. of patients 90 89 -
Male (proportion in %) 51 (57) 60 (67) 0.16
Female (proportion in %) 39 (43) 29 (33)  
Age (years): median 10.4 7.2 0.52
   IQRΔ 5.2 to 14.7 3.7 to 16.1  
   Range 0.2 to 35.2 0.0 to 35.4  
CVAD utilization days    
   Cumulative No. 6,086 6,705 #
   Port 3,672 3,989  
   Broviac 2,414 2,716  
Malignancy No. (%)    0.09
   ALL 21 (23) 26 (29)  
   AML 3 (3) 6 (7)  
   NHL and HD 15 (17) 7 (8)  
   Solid tumor 30 (33) 22 (25)  
   ZNS 18 (20) 27 (30)  
   MAS 2 (2) 0 (0)  
   MDS 0 (0) 1 (1)  
   LCH 1 (1) 0 (0)  
Malignancy in relapse No. (%) 16 (18) 13 (15) 0.69
No of patients with    0.41
Port (proportion in %) 68 (76) 62 (70)  
Broviac (proportion in %) 22 (24) 27 (30)  
CVAD removal due to infection: No. (%) 4 (4.4) 3 (3.4)Ω 1.00
  1. Group 1 = heparin (2003–2005) vs. group 2 = TauroLock™ (2005–2007)
  2. MAS Hemophagocytic lymphohistiocytosis, MDS myelodysplastic syndrome,
  3. LCH Langerhans Cell Histiocytosis.
  4. * CoNS = Coagulase-negative staphylococci.
  5. Δ IQR = Interquartile range, 25–75. Percentile
  6. # Utilization days per individual patient were not available; thus, P-values could not be calculated.
  7. Ω None of these due to Gram positive infections caused by CoNS or MRSE